Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Ferring sales and marketing update

    Ferring launched Noqdirna desmopressin in the U.K. to treat nocturia due to idiopathic nocturnal polyuria. The NHS list price of the freeze-dried formulation of a vasopressin analog is 15.16 ($18.46) for 30 tablets of …

    Published on 11/7/2016
  • PaxVax sales and marketing update

    PaxVax launched Vaxchora (PXVX0200) in the U.S. to prevent cholera caused by serogroup O1 in adults aged 18 to 64 traveling to cholera-affected areas. The live attenuated vaccine against Vibrio cholerae is the only FDA-…

    Published on 11/7/2016
  • Tagrisso sales and marketing update

    The U.K.'s NICE issued final guidance recommending that Tagrisso osimertinib from AstraZeneca be covered by the Cancer Drugs Fund for locally advanced or metastatic T790M EGFR mutation-positive non-small cell lung …

    Published on 11/7/2016
  • Taltz sales and marketing update

    The U.K.s NICE issued draft guidance recommending the use of Taltz ixekizumab from Lilly to treat plaque psoriasis in patients with severe disease and whose disease has not responded to standard systemic therapies or …

    Published on 11/7/2016
  • Zepatier sales and marketing update

    The U.K.'s NICE issued final guidance recommending the use of Zepatier grazoprevir/elbasvir from Merck to treat HCV genotypes 1a, 1b and 4 infection in adults. The guidance is in line with a final appraisal …

    Published on 11/7/2016
  • Alnylam sales and marketing update

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Business: Endocrine/Metabolic Alnylam launched an early access program in the U.S. for patisiran to treat patients with symptomatic hereditary transthyretin (…

    Published on 10/31/2016
  • Amicus Therapeutics sales and marketing update

    Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Business: Endocrine/Metabolic The U.K.s NICE issued draft guidance recommending the use of Galafold migalastat from Amicus to treat Fabrys disease in patients at …

    Published on 10/31/2016
  • Bristol-Myers, Ono Pharmaceutical sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer The U.K.s NICE issued final draft guidance recommending the use of Opdivo nivolumab from …

    Published on 10/31/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune The U.K.s NICE published final draft guidance recommending the use of Otezla apremilast from Celgene to treat moderate to severe chronic plaque psoriasis …

    Published on 10/31/2016
  • Exelixis, Genentech, Roche sales and marketing update

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer The U.K.s NICE issued final guidance recommending …

    Published on 10/31/2016
  • Quest Diagnostics, IBM, Memorial Sloan Kettering, The Broad Institute of MIT and Harvard sales and marketing update

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. IBM (NYSE:IBM), Armonk, N.Y. Memorial Sloan Kettering Cancer Center, New York, N.Y. The Broad Institute of MIT and Harvard, Cambridge, Mass. Business: Genomics, Cancer …

    Published on 10/31/2016
  • Sarepta Therapeutics sales and marketing update

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Musculoskeletal In a policy statement, Humana Inc. (NYSE:HUM, Louisville, Ky.) said it will cover Exondys 51 eteplirsen from Sarepta to treat Duchenne …

    Published on 10/31/2016
  • UCB sales and marketing update

    UCB Group (Euronext:UCB), Brussels, Belgium Business: Autoimmune The U.K.s NICE issued final guidance recommending the use of Cimzia certolizumab pegol from UCB with or without methotrexate to treat severe rheumatoid …

    Published on 10/31/2016
  • 10x Genomics sales and marketing update

    10x Genomics Inc., Pleasanton, Calif. Business: Genomics 10x launched the Chromium Single Cell Controller for single-cell analytics in the U.S. for $50,000. The company did not respond to inquiries.

    Published on 10/24/2016
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Endocrine/Metabolic The U.K.s NICE issued a final appraisal determination (FAD) recommending that Forxiga dapagliflozin from AstraZeneca can be added as a cost…

    Published on 10/24/2016
  • Biofrontera sales and marketing update

    Biofrontera AG (Xetra:B8F), Leverkusen, Germany Business: Dermatology Biofrontera launched Ameluz aminolevulinic acid and the BF-RhodoLED lamp in the U.S. Ameluz is approved as photodynamic therapy therapy (PDT) using …

    Published on 10/24/2016
  • J&J sales and marketing update

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that added benefit for Imbruvica ibrutinib from…

    Published on 10/24/2016
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Autoimmune, Biosimilars Pfizer will launch Inflectra infliximab-dyyb, a biosimilar of Remicade infliximab, in the U.S. late next month. The product is approved to treat …

    Published on 10/24/2016
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a second early benefit assessment that additional data from Pfizer concerning Xalkori …

    Published on 10/24/2016
  • AbbVie, J&J sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Imbruvica ibrutinib from Johnson & Johnson …

    Published on 10/17/2016
  • Aetna, Merck sales and marketing update

    Aetna Inc. (NYSE:AET), Hartford, Conn. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Endocrine/Metabolic Aetna and Merck signed a value-based contract covering diabetes drugs Januvia sitagliptin and Janumet …

    Published on 10/17/2016
  • Anthem, Sarepta Therapeutics sales and marketing update

    Anthem Inc. (NYSE:ANTM), Indianapolis, Ind. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Musculoskeletal Anthem said it will not cover Exondys 51 eteplirsen from Sarepta to treat Duchenne muscular…

    Published on 10/17/2016
  • Bristol-Myers sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer The U.K.s NICE issued two draft guidances requesting Bristol-Myers Squibb make a case for the inclusion of Opdivo nivolumab in the Cancer Drugs Fund (…

    Published on 10/17/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune The U.K.s NICE issued updated draft guidance recommending the use of Otezla apremilast from Celgene to treat psoriatic arthritis in patients not responding …

    Published on 10/17/2016
  • Aralez sales and marketing update

    Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ; TSX:ARZ), Milton, Ontario Business: Cardiovascular Aralez launched once-daily Yosprala 325/40 (PA32540) and Yosprala 81/40 (PA8140) in the U.S. for the secondary prevention of …

    Published on 10/10/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993